RecruitingNCT07703683

Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases


Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Enrollment

100 participants

Start Date

Feb 19, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GLP-1 Receptor Agonists for people with cushing syndrome, diabetes, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGLP-1 Receptor Agonists

Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity


Locations(1)

Cliniques Universitaires Saint-Luc

Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07703683


Related Trials